ClinConnect ClinConnect Logo
Search / Trial NCT03272607

Reducing Post-discharge Adverse Drug Events Amongst the Elderly: a Multi-centre Electronic Deprescribing Intervention

Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Sep 1, 2017

Trial Information

Current as of July 21, 2025

Completed

Keywords

Adverse Drug Event Choosing Wisely Canada Deprescribing Elderly Frailty High Value Healthcare Medication Rationalization Medication Stewardship Polypharmacy

ClinConnect Summary

Polypharmacy, or the concomitant use of 5 drugs or more, is a serious health concern and affects more than half of Canadians aged 65 years and older. It is the number one identifiable risk factor for adverse drug events (ADEs), which are responsible for 27,000 hospital admissions annually in Canada and up to 20% of return visits to the hospital within 30 days of discharge. Many ADEs are preventable or ameliorable through interventions to reduce inappropriate prescribing.

MedSafer, the intervention software, applies an electronic set of criteria, previously designed and piloted on one thous...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • patients aged 65 years and older
  • patients who take five or more medications in the community
  • patients who are cognitively impaired or otherwise unable to provide consent will still be included as this subpopulation of patients may be at greatest risk of ADEs because of their communication problems.
  • Exclusion Criteria:
  • patients who take four or fewer medications in the community
  • patients expected to die within 30 days or be transferred to a palliative care unit/another hospital
  • patients without provincial health insurance or who normally live outside that province
  • patients previously enrolled
  • inability for patient or proxy to speak English or French
  • no means of contacting patient or proxy post-discharge
  • Patients discharged from non-study units will be excluded unless that unit is a transitional care, rehabilitation, or post-acute care unit which bridges the gap between acute medical hospitalization and community services.

About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre

The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.

Locations

Kingston, Ontario, Canada

Ottawa, Ontario, Canada

Kingston, Ontario, Canada

Montreal, Quebec, Canada

Calgary, Alberta, Canada

Edmonton, Alberta, Canada

Vancouver, British Columbia, Canada

Toronto, Ontario, Canada

Patients applied

0 patients applied

Trial Officials

Todd C Lee, MD, MPH

Principal Investigator

McGill University Health Centre/Research Institute of the McGill University Health Centre

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials